Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart scan could spot salvageable muscle after attack

NCT ID NCT07443696

Diagnosis Sponsor: Sinotau Pharmaceutical Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new PET imaging method that uses a special tracer called XTR003 along with FDG to see which parts of the heart are still alive in people with heart failure from blocked arteries. About 40 to 60 participants will be randomly assigned to receive either the new fasting imaging method or a standard glucose-loaded scan. The goal is to see if the new method better predicts which heart regions will improve after surgery to restore blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XTR003 injection (a fatty-acid tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors better identify which heart muscle is still alive and could recover after surgery.
What could go wrong
This is a small, early-phase study with only 40-60 participants. The new imaging method may not prove more accurate than existing tests, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 85 years, regardless of gender. 2. Diagnosed with ischemic cardiomyopathy (ICM). 3. significant coronary artery disease (CAD). 4. Left ventricular systolic dysfunction, with LVEF ranging from \>20% to ≤40% 5. Assessed by a team of cardiac surgeons/operators as suitable for complete revascularization. 6. Capable of effective communication with the investigators, able to understand and comply with the clinical study requirements, voluntarily participate in the study, and provide written informed consent after being fully informed. Exclusion Criteria: 1. Decompensated heart failure within 48 hours prior to enrollment. 2. Recent ST-segment elevation myocardial infarction (STEMI) within less than 4 weeks. 3. Left ventricular aneurysm. 4. Judged by the investigator as unable to complete PET examination. 5. Severe renal insufficiency. 6. Severe hepatic insufficiency. 7. Subjects with fever or active infectious diseases who are assessed by the investigator as unsuitable for study participation. 8. Pregnant or lactating women. 9. Contraindications to magnetic resonance imaging (MRI), such as claustrophobia or intracorporeal metallic implants. 10. Subjects with mental disorders or poor compliance. 11. Significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv per year) or exposure to radioactive substances/ionizing radiation for therapeutic or research purposes within the past 10 years. 12. Other circumstances deemed by the investigator as unsuitable for trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Ischemic cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

  • Beijing Chaoyang Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, China

  • TEDA International Cardiovascular Hospital

    NOT_YET_RECRUITING

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.